Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 9/20 | 0.55 |
| ▸ | NQO1 | P15559 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698688 | 0.98 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL30177134 | 0.98 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| Phosphoric Acid SCHEMBL3361101 | 0.90 | HSD17B3 (0.59) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| Diethylamine SCHEMBL1771393 | 0.86 | ALDH1A1 (0.51) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL1771050 | 0.84 | CYP1A2 (0.51) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| Esculetin SCHEMBL4065440 | 0.83 | MCL1 (0.61) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL4620259 | 0.82 | KDM4E (0.68) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL28134048 | 0.82 | KDM4E (0.50) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL7819347 | 0.80 | NQO1 (0.56) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E | |
| SCHEMBL15842388 | 0.80 | NQO1 (0.56) | ALDH1A1HPGDHSD17B10HSD17B3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150130-A2 | NECROSIS INHIBITOR | LINKGEVITY LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-20230256052-A1 | METHOD AND COMPOSITION FOR REDUCING OR PREVENTING BONE RESORPTION | UNIVERSITY OF CONNECTICUT | 2023-08-17 | — | — | US | disclosed |
| US-20200147070-A1 | INDUCING PHOSPHOLIPIDOSIS FOR ENHANCING THERAPEUTIC EFFICACY | Nextcea Inc. | 2020-05-14 | — | — | US | disclosed |
| CN-105849323-A | Allergen detection | 多茨设备公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20150306193-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE CONDITIONS, INCLUDING TYPE 1 DIABETES | UNIVERSITY OF ROCHESTER | 2015-10-29 | — | — | US | disclosed |
| US-20140302509-A1 | PROCATHEPSIN L AND CATHEPSIN L AS BIOMARKERS FOR ISCHEMIA | MYCARTIS NV (BE) | 2014-10-09 | — | — | US | disclosed |
| EP-2766734-A1 | PROCATHEPSIN L AND CATHEPSIN L AS BIOMARKERS FOR ISCHEMIA | Pronota NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014085767-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE CONDITIONS, INCLUDING TYPE1 DIABETES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2013053916-A1 | PROCATHEPSIN L AND CATHEPSIN L AS BIOMARKERS FOR ISCHEMIA | PRONOTA N.V. (BE) | 2013-04-18 | — | — | WO | disclosed |
| US-8114619-B2 | Methods for diagnosis and optimizing treatment of multiple sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100137420-A1 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| WO-2007109733-A2 | DIAGNOSTIC AND PROGNOSTIC MARKERS AND TREATMENT STRATEGIES FOR MULTIPLE SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-0820453-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-0820453-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031504-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137420-A1 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis | CTSB, CSTB, CTSG | ALDH1A1 4725/4885HPGD 2682/4885HSD17B10 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.